TKP Masthead

Hype Cycle Alert: Play This Biotech Breakout For Big Gains

Welcome to your Hype Cycle Insider report!

Remember, these monthly bonus reports exclusively for Technology Profits Confidential PRO readers pull back the curtain on a stock that's ramping up the innovation curve so that you can act before mainstream investors are paying attention.

Driven by a spate of high-profile buyouts since spring, biotech has been hot! The S&P Biotech ETF, which tracks the biotech sector, has risen 20% since early April. 

Biotech buyouts are driven by Big Pharma greed. Commercial-stage pharmaceutical companies own perishable assets in the form of patent drugs, drugs which can suddenly be worth much less when they come off patent and generic competition hits.

So, besides internal research and development, pharmaceutical companies with enough cash often go out and buy promising junior players—biotechs--with assets either looking like they will succeed in the market, or are already doing so. 

Axsome Therapeutics (NASDAQ: AXSM) could be one of those companies. The $3.69 billion company has been trading in a range all year, but earlier this month started to break out, suggesting higher share prices are in its future.

chart

Investors have good reason to get excited about Axsome. The company has been developing a new drug to treat major depressive disorder. The drug, called AXS-05, targets receptors of the central nervous system. 

AXS-05 is a proprietary formulation consisting of two components. One is dextromethorphan (DM), a common component of cough suppressants. The second is bupropion, an existing antidepressant. The combination drug is formulated in such a way as to inhibit the metabolism of DM, so it can stay in the brain longer, where it can modulate an array of cell receptors and neurotransmitters. Bupropion itself is used to treat depression, where it affects neurotransmitters like dopamine as well as norepinephrine. Combining the two is synergistic, with bupropion increasing the bioavailability of DM.

In Phase 3 trials AXS-05 showed a marked diminution in depressive symptoms, with 53% scoring improvements compared to only 33% on placebo. On another measure, 47% of patients reported feeling much, or very much improved when taking the drug.

Success in this Phase 3 trial sets Axsome up for a new drug application at the FDA, something it plans to do in the fourth quarter of this year. Since AXS-05 has already received Breakthrough Therapy Designation from the FDA, I believe it is highly likely Axsome will see this drug receive priority review, too. Priority means the review and decision on AXS-05’s application would only take 6 months instead of 10 months.

The FDA approved Axsome’s depression treatment last October, and the company is steadily growing sales numbers. But AXS-05 is also in Phase 3 clinical development for Alzheimer’s Disease agitation, as well as a smoking cessation aid. Add to that an additional three drugs in the pipeline. One drug is AXS-07, which the company expects to file for regulatory approval next quarter for migraines. Another, AXS-12, is expected to generate results from a Phase 3 trial in narcolepsy later this month.

But the real shocker is what Axsome believes its drugs will generate in terms of sales. Axsome expects that once approved, its stable of new drugs could pull in up to $11.5 billion, implying a huge upside from its current price. Even analysts' forecasts, which don’t include the sales potential for all of Axsome’s drugs, range up to $4.5 billion per year—still a huge opportunity at current prices. 

That makes this month’s breakout in AXSM shares a great buy opportunity.

Consider buying shares of Axsome Therapeutics (NASDAQ: AXSM)

Important Note: As a reminder, Hype Cycle Insider picks are an exclusive bonus benefit for Technology Profits Confidential PRO readers like you but they aren’t official Tech Profits Confidential recommendations. That means we won't track this stock in our model portfolio. If you choose to buy, plan your entry and exit carefully. Never invest money you can't afford to lose.

Want More Technology Profits Confidential Pro?

Do you like this content? Would you like to know more? Because we have this and much more to share with you. Get started today!

awn-hero-img-09-05-25

A Green Light for American Birthright Opportunities

The mailbag included questions on Trump’s deregulating agenda, century bonds, and Trump’s huge blunder.

Read More

lir-update-09-04-25-img-post

Market Leaders Give Way For Rotation Trades

We are really starting to see the cracks show in the current market leadership right now… And investors are starting to recognize a noticeable change in what’s working in the market.

Read More

ALN-alert-08-27-25(Featured)

The Pentagon Just Validated Our Nuclear Bet

Our nuclear play got caught up in the recent market volatility, and it’s opening up another great opportunity to get in on this play at the forefront of a technology that even the Pentagon now considers a must-have. Here’s why…

Read More

awn-hero-img-08-22-25

The Jackson Hole Speech: Markets Approve

The mailbag included questions on GPT-5 and AI valuations, the defense sector, and the future for the Chinese economy.

Read More

What Ends the War in Ukraine? More Oil

Trump heads to Alaska for a high stakes meeting with Putin to negotiate the end of the War in Ukraine. But what will it take to end the war? In today’s state of the market briefing, Jim warns why the current move of secondary sanctions won’t work and reveals the solution that will.

Read More

ALN0UPDATE-07-31-25-IMG-POST

OpenAI's Open Relationship

AI infrastructure is the must-have for businesses building out the trillion-dollar tech, which is why industry leaders are scrambling to secure new multi-billion dollar deals to shore up their access. Today, we look at the big winners in this scramble for precious computing resources…

Read More

lir-update-07-24-25-img post

Overbought Conditions Can Resolve in a Variety of Ways

We’re seeing a lot of talk about overbought conditions right now across the market. The financial media loves to talk a big game about pullbacks and anything that will get investors fearful and clicking on their headlines.

Read More

The Beautiful Bill: How It Impacts You

President Trump’s One Big Beautiful Bill is now law. But what’s in it and how will it impact you? Jim provides analysis on the bill and details what provisions and funding are included in this major piece of legislation that impacts you and your money.

Read More

ALN-UPDATE-07-09-25-IMG-POST

Elon’s New $2 Trillion Grid Empire

The automotive media were in a tizzy when Tesla reported falling car sales last week. But buried beneath the headlines was Tesla’s rising sales in a new line of business that’s becoming crucial to the AI Revolution. Ray Blanco gives you the full story…

Read More

The Case for Treasuries

Is the world ditching the dollar and are U.S. institutions ditching U.S. bonds? In his latest SitRep, Jim analyzes the biggest misconception in capital markets today and provides details on what’s really going on in the Treasury market.

Read More